Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study.

Jeon JY, Kovanlikaya I, Boockvar JA, Mao X, Shin B, K Burkhardt J, Kesavabhotla K, Christos P, Riina H, Shungu DC, Tsiouris AJ.

AJNR Am J Neuroradiol. 2012 Dec;33(11):2095-102. doi: 10.3174/ajnr.A3091. Epub 2012 May 10.

2.

3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.

Muruganandham M, Clerkin PP, Smith BJ, Anderson CM, Morris A, Capizzano AA, Magnotta V, McGuire SM, Smith MC, Bayouth JE, Buatti JM.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):181-9. doi: 10.1016/j.ijrobp.2014.05.014. Epub 2014 Jun 28.

3.

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.

Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):936-44. doi: 10.1093/neuonc/not044. Epub 2013 May 3.

4.

Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.

Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, Seedial SM, Pannullo SC, Schwartz TH, Stieg P, Zimmerman RD, Knopman J, Scheff RJ, Christos P, Vallabhajosula S, Riina HA.

J Neurosurg. 2011 Mar;114(3):624-32. doi: 10.3171/2010.9.JNS101223. Epub 2010 Oct 22.

5.

Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.

Stadlbauer A, Pichler P, Karl M, Brandner S, Lerch C, Renner B, Heinz G.

Eur J Radiol. 2015 Jun;84(6):1128-36. doi: 10.1016/j.ejrad.2015.02.025. Epub 2015 Mar 6.

PMID:
25795194
6.

Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.

Artzi M, Bokstein F, Blumenthal DT, Aizenstein O, Liberman G, Corn BW, Ben Bashat D.

Eur J Radiol. 2014 Jul;83(7):1250-6. doi: 10.1016/j.ejrad.2014.03.026. Epub 2014 Apr 12.

PMID:
24809637
7.

Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.

Kim H, Catana C, Ratai EM, Andronesi OC, Jennings DL, Batchelor TT, Jain RK, Sorensen AG.

Cancer Res. 2011 Jun 1;71(11):3745-52. doi: 10.1158/0008-5472.CAN-10-2991. Epub 2011 Apr 20.

8.

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.

Hattingen E, Jurcoane A, Bähr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U.

Neuro Oncol. 2011 Dec;13(12):1349-63. doi: 10.1093/neuonc/nor132. Epub 2011 Sep 2.

9.

Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.

Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, Tsiouris AJ, Boockvar JA.

World Neurosurg. 2012 Jan;77(1):130-4. doi: 10.1016/j.wneu.2011.05.056. Epub 2011 Nov 21.

10.

Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.

Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP, Nelson SJ.

J Magn Reson Imaging. 2004 May;19(5):546-54.

PMID:
15112303
11.

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.

Guillevin R, Menuel C, Taillibert S, Capelle L, Costalat R, Abud L, Habas C, De Marco G, Hoang-Xuan K, Chiras J, Vallée JN.

Br J Cancer. 2011 Jun 7;104(12):1854-61. doi: 10.1038/bjc.2011.174. Epub 2011 May 24.

12.

MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.

Elias AE, Carlos RC, Smith EA, Frechtling D, George B, Maly P, Sundgren PC.

Acad Radiol. 2011 Sep;18(9):1101-8. doi: 10.1016/j.acra.2011.05.006.

PMID:
21820634
13.

Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.

Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D, Bachaud JM, Berry I, Moyal EC.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):773-81. doi: 10.1016/j.ijrobp.2007.10.039.

PMID:
18262090
14.

Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy.

Hattingen E, Bähr O, Rieger J, Blasel S, Steinbach J, Pilatus U.

PLoS One. 2013;8(3):e56439. doi: 10.1371/journal.pone.0056439. Epub 2013 Mar 8.

15.

Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab.

Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB.

J Neurooncol. 2012 Jan;106(1):111-9. doi: 10.1007/s11060-011-0638-x. Epub 2011 Jun 25.

PMID:
21706273
16.

Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.

Riina HA, Fraser JF, Fralin S, Knopman J, Scheff RJ, Boockvar JA.

J Exp Ther Oncol. 2009;8(2):145-50.

PMID:
20192120
17.

In vivo differentiation of aerobic brain abscesses and necrotic glioblastomas multiforme using proton MR spectroscopic imaging.

Lai PH, Weng HH, Chen CY, Hsu SS, Ding S, Ko CW, Fu JH, Liang HL, Chen KH.

AJNR Am J Neuroradiol. 2008 Sep;29(8):1511-8. doi: 10.3174/ajnr.A1130. Epub 2008 May 22.

18.

Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy.

Singh R, Kesavabhotla K, Kishore SA, Zhou Z, Tsiouris AJ, Filippi CG, Boockvar JA, Kovanlikaya I.

AJNR Am J Neuroradiol. 2016 May 26. [Epub ahead of print]

PMID:
27231225
19.

MR spectroscopy differentiation between high and low grade astrocytomas: a comparison between paediatric and adult tumours.

Porto L, Kieslich M, Franz K, Lehrnbecher T, Zanella F, Pilatus U, Hattingen E.

Eur J Paediatr Neurol. 2011 May;15(3):214-21. doi: 10.1016/j.ejpn.2010.11.003. Epub 2010 Dec 9.

PMID:
21145271
20.

Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury.

Zeng QS, Li CF, Zhang K, Liu H, Kang XS, Zhen JH.

J Neurooncol. 2007 Aug;84(1):63-9. Epub 2007 Feb 14.

PMID:
17619225
Items per page

Supplemental Content

Write to the Help Desk